NASDAQ:EPZM - Epizyme Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$5.94 +0.06 (+1.02 %)
(As of 12/18/2018 06:00 AM ET)
Previous Close$5.88
Today's Range$5.64 - $6.28
52-Week Range$5.64 - $21.40
Volume776,965 shs
Average Volume547,052 shs
Market Capitalization$465.51 million
P/E RatioN/A
Dividend YieldN/A
Beta2.09
Epizyme, Inc., a clinical stage biopharmaceutical company, discovers and develops novel epigenetic medicines for patients with cancer and other diseases in the United States. Its product candidates include tazemetostat, an inhibitor of the EZH2, which is in Phase II clinical trial for patients with relapsed or refractory non-hodgkin lymphoma (NHL); Phase II clinical trial for relapsed or refractory patients with mesothelioma; Phase I dose-escalation and expansion study for children with INI1-negative solid tumors; Phase II clinical trials for patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL); Phase Ib/II clinical trial in elderly patients with DLBCL; and Phase II clinical trial for relapsed or refractory patients with mesothelioma characterized by BAP1 loss-of-function,; and Phase Ib/II clinical trial for the treatment of patients with relapsed or refractory metastatic non-small cell lung cancer, as well as Phase II clinical trial in adult patients with ovarian cancer. The company is also developing additional programs, such as pinometostat, an intravenously administered small molecule inhibitor of DOT1L for the treatment of acute leukemias; and PRMT5 inhibitor that is in Phase I clinical trial for patients with solid tumors and NHL. Epizyme, Inc. has collaboration agreements with Celgene Corporation; Genentech Inc.; Glaxo Group Limited; Roche Molecular Systems, Inc.; Eisai Co. Ltd.; Lymphoma Study Association; and Boehringer Ingelheim. The company was founded in 2007 and is headquartered in Cambridge, Massachusetts.

Receive EPZM News and Ratings via Email

Sign-up to receive the latest news and ratings for EPZM and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:EPZM
Previous Symbol
CUSIPN/A
Phone617-229-5872

Debt

Debt-to-Equity RatioN/A
Current Ratio7.48
Quick Ratio7.48

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$10 million
Price / Sales47.03
Cash FlowN/A
Price / Cash FlowN/A
Book Value$3.40 per share
Price / Book1.75

Profitability

EPS (Most Recent Fiscal Year)($2.18)
Net Income$-134,300,000.00
Net MarginsN/A
Return on Equity-64.87%
Return on Assets-55.18%

Miscellaneous

Employees131
Outstanding Shares79,170,000
Market Cap$465.51 million
OptionableOptionable

Epizyme (NASDAQ:EPZM) Frequently Asked Questions

What is Epizyme's stock symbol?

Epizyme trades on the NASDAQ under the ticker symbol "EPZM."

How were Epizyme's earnings last quarter?

Epizyme Inc (NASDAQ:EPZM) released its quarterly earnings results on Friday, November, 2nd. The biopharmaceutical company reported ($0.54) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.61) by $0.07. View Epizyme's Earnings History.

When is Epizyme's next earnings date?

Epizyme is scheduled to release their next quarterly earnings announcement on Tuesday, March 12th 2019. View Earnings Estimates for Epizyme.

What price target have analysts set for EPZM?

9 Wall Street analysts have issued 12-month target prices for Epizyme's stock. Their forecasts range from $11.00 to $27.00. On average, they expect Epizyme's stock price to reach $20.3750 in the next year. This suggests a possible upside of 243.0% from the stock's current price. View Analyst Price Targets for Epizyme.

What is the consensus analysts' recommendation for Epizyme?

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Epizyme in the last year. There are currently 2 hold ratings and 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Epizyme.

Has Epizyme been receiving favorable news coverage?

News articles about EPZM stock have trended somewhat positive on Tuesday, InfoTrie reports. The research firm scores the sentiment of news coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Epizyme earned a daily sentiment score of 1.7 on InfoTrie's scale. They also gave news coverage about the biopharmaceutical company a news buzz of 7.0 out of 10, indicating that recent news coverage is likely to have an impact on the company's share price in the next few days.

Who are some of Epizyme's key competitors?

Who are Epizyme's key executives?

Epizyme's management team includes the folowing people:
  • Mr. Robert B. Bazemore Jr., Pres, CEO, Sec. & Director (Age 50)
  • Mr. Matthew E. Ros, Chief Strategy & Bus. Officer (Age 51)
  • Dr. H. Robert Horvitz, Co-Founder & Chairman of the Scientific Advisory Board
  • Dr. Yi Zhang, Scientific Co-Founder & Member of The Scientific Advisory Board
  • Ms. Suzanne Fleming, Principal Financial Officer, Sr. VP of Fin., Treasurer & Principal Accounting Officer (Age 57)

Who are Epizyme's major shareholders?

Epizyme's stock is owned by a variety of of retail and institutional investors. Top institutional investors include Primecap Management Co. CA (12.21%), Vanguard Group Inc. (5.77%), Vanguard Group Inc (5.77%), BlackRock Inc. (5.51%), FMR LLC (4.63%) and Redmile Group LLC (2.84%). Company insiders that own Epizyme stock include Andrew E Singer, David M Mott, Matthew Ros, Peter Tai-Ching Ho and Robert A Copeland. View Institutional Ownership Trends for Epizyme.

Which major investors are selling Epizyme stock?

EPZM stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Citadel Advisors LLC, Oracle Investment Management Inc., Opaleye Management Inc., TIAA CREF Investment Management LLC, Morgan Stanley, Macquarie Group Ltd. and Foresite Capital Management II LLC. View Insider Buying and Selling for Epizyme.

Which major investors are buying Epizyme stock?

EPZM stock was bought by a variety of institutional investors in the last quarter, including Point72 Asset Management L.P., Marshall Wace LLP, Sofinnova Ventures Inc, Dimensional Fund Advisors LP, Redmile Group LLC, University of Notre Dame DU Lac, Sphera Funds Management LTD. and Vanguard Group Inc. View Insider Buying and Selling for Epizyme.

How do I buy shares of Epizyme?

Shares of EPZM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Epizyme's stock price today?

One share of EPZM stock can currently be purchased for approximately $5.94.

How big of a company is Epizyme?

Epizyme has a market capitalization of $465.51 million and generates $10 million in revenue each year. The biopharmaceutical company earns $-134,300,000.00 in net income (profit) each year or ($2.18) on an earnings per share basis. Epizyme employs 131 workers across the globe.

What is Epizyme's official website?

The official website for Epizyme is http://www.epizyme.com.

How can I contact Epizyme?

Epizyme's mailing address is 400 TECHNOLOGY SQUARE, CAMBRIDGE MA, 02139. The biopharmaceutical company can be reached via phone at 617-229-5872 or via email at [email protected]


MarketBeat Community Rating for Epizyme (NASDAQ EPZM)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  352 (Vote Outperform)
Underperform Votes:  261 (Vote Underperform)
Total Votes:  613
MarketBeat's community ratings are surveys of what our community members think about Epizyme and other stocks. Vote "Outperform" if you believe EPZM will outperform the S&P 500 over the long term. Vote "Underperform" if you believe EPZM will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/18/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel